Send to

Choose Destination

See 1 citation found using an alternative search:

Reumatol Clin. 2016 Jul-Aug;12(4):210-5. doi: 10.1016/j.reuma.2016.01.001. Epub 2016 Feb 18.

Rituximab in lupus nephritis: A non-systematic review.

[Article in English, Spanish]

Author information

Unidad de Enfermedades Reumáticas y Autoinmunes (UNERA), Guayaquil, Ecuador; Facultad de Ciencias Médicas, Universidad Espíritu Santo, Guayaquil, Ecuador.
Facultad de Ciencias Médicas, Universidad Espíritu Santo, Guayaquil, Ecuador. Electronic address:


Lupus nephritis (LN) is a common and severe complication in patients with lupus. Current therapy is based on immunosuppressive drugs and glucocorticoids. Recently, rituximab has been proposed as an alternative treatment for LN. Rituximab is a monoclonal antibody directed against the CD20 antigen receptor on B cells. The aim of this review is to summarize all the available information about rituximab in LN. Eleven studies were found; three of them were observational studies (2 prospective and 1 retrospective) and eight were clinical trials (7 open-label studies and only 1 randomized controlled trial [RCT]). The evidence is insufficient to establish the role of rituximab in the treatment of LN. Results from the only RCT, which were negative, suggest a clinical benefit in black people. Further studies must confirm this hypothesis. Controlled clinical trials involving adaptive randomization are required to establish the real benefit of rituximab in LN.


Lupus; Nefritis; Nephritis; Rituximab

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center